SGMT · Sagimet Biosciences Inc.
$7.27
-0.18 (-2.42%)
At close · Jul 28
Market Cap
$448.94M
Shares
61.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.45
Open$7.12
Day$7.03–7.59
52W$4.50–11.41
Avg vol 30d1.3M
Short int9.7M · 15.8% float · 9.2d
Short vol58%
Last earningsMay 12, 2026
DataJul 2023–Jul 2026
Filing10-Q · May 12
Up next
Next earnings call
Mar 26, 2027
Est · unconfirmed
· in 34 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+31%
trailing
YTD return
+26%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
12 of 88 funds reported for Jun 30 · net +4.6K sh shares · +4 new
Insider flow
Distributing
Net -$578.9K over 90 days · 100% sells
Short interest
Rising
15.78% of float · ▲ +18.1% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
88 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Balance sheet
$35.0M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
12 of 88 funds reported for Jun 30 · net +4.6K sh shares · +4 new
Insider flow
Distributing
Net -$578.9K over 90 days · 100% sells
Short interest
Rising
15.78% of float · ▲ +18.1% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
88 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $7 · 43%
52-wk high $11
vs 200-day avg +13%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGMT
this stock
Sagimet Biosciences Inc.
|
$448.94M | +25.8% | +0.0% | — | 15.8% |
|
ONC
BeOne Medicines Ltd.
|
$477.60B | +7.3% | +22179.2% | 971.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGMT | -4.7% | +8.6% | +31.4% | -3.6% | +25.8% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | -4.3% | +7.2% | +25.1% | -2.6% | +17.5% |
Key facts
CIK
1400118
CUSIP
786700104
13F (30d)
12 filings
12 filers
Visit website
Investor relations